期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

法舒地尔对冠心病患者介入治疗的临床研究 被引量：2

下载PDF
导出
摘要 目的观察法舒地尔注射液对冠心病介入治疗的临床疗效。方法选择110例均行冠脉造影证实,并行经皮腔内冠状动脉成形术(PTCA)+支架植入术冠心病患者,随机分两组,两组均常规接受正规冠心病二级预防治疗,包括阿司匹林75～150mg/d、硫酸氯吡格雷(波立维)75mg/d的双重抗血小板治疗,积极控制冠心病危险因素如血脂、血压和血糖的控制。治疗组加用法舒地尔注射液10ml(天津红日药业有限公司生产)加入5%葡萄糖注射液或0.9%氯化钠注射液100ml静脉输注,2次/d。疗程14d。结果治疗组心绞痛复发率显著低于对照组。治疗组再狭窄率为3.57%,对照组再狭窄率为18.52%,治疗组显著低于对照组(P<0.01)。结论法舒地尔注射液对预防冠脉内支架置入术后心脏事件预防及再狭窄有较好的疗效。
作者 廖驰林 刘华勇 梁东 潘国州 黄梦照
机构地区 百色市人民医院心内科
出处 《中国实用医药》 2010年第21期158-159,共2页 China Practical Medicine
关键词 法舒地尔 介入治疗 冠心病
分类号 R541.4 [医药卫生—心血管疾病]
  • 相关文献

参考文献6

  • 1Gaspardone A,Crea F,Versaci F,et al.Predictive value ofC-reactive protein after successful coronary-artery stentingin patients with stable angina.Am J Cardiol,1998,82(4):515-518.
  • 2Pieterma A,Kofflard M,Dewitl E,et al.Late human loss after coronary angioplasty is associated with the activation status of circulating phagocytes before treatment.Circulation,1995,91(5):1320-1325.
  • 3Nagumo H,Sasaki Y,Ono Y,et al.Rho kinase inhibitor HA-1077 prevents Rho-mediated myosin phosphatase inhibition in smooth muscle cells.Am J Physiol Cell Physiol,2000,278(1):C57-C65.
  • 4Masumoto A,Mohri M,Shimokawa H,et al.Suppression ofcoronary artery spasm by the RhO2kinase inhibitor fasudil in pa2tients with vasospastic angina.Circulation,2002,105 (13):1545-1547.
  • 5Matsumoto Y,Uwatoku T,Oi K,et al.Long-term inhibition of Rho-kinase suppresses neointimal formation after stent im-plantation in porcine coronary arteries:Involvement of multiple mechanisms.Arterioscler Thromb Vasc Biol,2004,24:181.
  • 6Shimokawa H,Morishige K,Miyata K,et al.Long-term inhibition of Rho-kinase induces a regression of arteriosclerotic coronary lesion in a porcine model in vivo.Cardiovasc Res,2001,51 (1):169-177.

同被引文献18

  • 1张占海.CTFC对冠脉直接支架置入术后血流评价作用[J].郑州大学学报（医学版）,2005,40(5):934-935. 被引量：4
  • 2Sadahiro S, Suzuki T, Tokunaga N, et al. Prevention of hepatic artery occlusion during eontinuous infusion of fluorouracil using liposteroid[J]. AJR, 2000, 175:1641 - 1642.
  • 3Lim bruno U,Micheli A,De Carlo M,et al.Mechanical prevention of distal embolization during primary angioplasty safety,feasibility,and impact on myocardial reperfusion[J].Circulation,2003,108(2):171-176.
  • 4Nagumo H,Sasaki Y,Ono Y,et al.Rho kinase inhibitor HA-1077 prevents Rho-mediated myosin phosphatase inhibition in smooth muscle cells[J].AM J Physiol Cell Physiol,2000,278(1):C57-C65.
  • 5Kensuke N,Naotangu O,Liao JK.Physiological role of ROC Ks in the cardiovascular system[J].Am J Physiol Cell Physiol,2006(90):C661-668.
  • 6Funakoshi Y,Ichiki T,Shiookawa H,et al.Rhokinase mediates angiotension II-induced monocyte chemottractant protein-l expression in rat vascular smooth muscle cells[J].Hypertension,2001,38(10):100-104.
  • 7Takeda K,Lchiki T,Tokunou T,el al.Critical role of Rhokinase and MEK/ERK pathways for angiotensin II induced plasminogen activator inhibitor type-4 gene expression[J].Arterioscler Thromb Vasc Biol,2001,21(5):868-873.
  • 8Sauzeau V,Mellbnnec E,Bertoglio J,et al.Human urotensin II-induced cont raction and arterial smooth muscle cell proliferation are mediated by RhoA and Rhokinase[J].Circ Res,2001,88(11):1102-1104.
  • 9Uehato M,Ishizaki T,Satoh H,el al.Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension[J].Nature,1997,389:990-994.
  • 10Masumoto A,Mohri M,Shimokawa H,et al.Suppression of coronary artery spasm by the Rho-kinase inhibitor fasudil in patients with vasospastic angina[J].Circulation,2002,105(13):1545-1547.

引证文献2

二级引证文献6

中国实用医药
2010年 第21期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部